By triggering the immune system’s response against tumors, cancer immunotherapy has revolutionized the treatment of many types of cancer. Numerous types of solid cancer are now being treated with immunotherapies that block checkpoint receptors like PD-1, proteins that restrict T cells’ ability to attack tumors. However, the introduction of PD-1-blocking agents frequently causes T cells to attack healthy tissues in addition to cancer cells, resulting in severe, occasionally fatal side effects that can lessen the advantages of immunotherapy. Researchers can now predict, treat, or even prevent the side effects of PD-1 blocking immunotherapies thanks to a recent study’s new insights into how the disease affects healthy tissues.
Study hints at how cancer immunotherapy can be safer
